Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Colomba E, Jonas SF, Eymard JC, Delva R, Brachet PE, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthélemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Narcisso B, Ladoire S, Berdah JF, Aisenfarb JB, Foulon S, Fizazi K. Colomba E, et al. Among authors: fizazi k. Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2. Eur Urol. 2024. PMID: 37271630 Clinical Trial.
Stage II Seminoma: Why Chemotherapy Should Remain a Standard.
Naoun N, Bernard-Tessier A, Fizazi K. Naoun N, et al. Among authors: fizazi k. Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar. Eur Urol Open Sci. 2023. PMID: 36793752 Free PMC article.
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, Soule H, Clarke NW, Collette L, Dignam JJ, Fizazi K, Paruleker WR, Sandler HM, Sydes MR, Tombal B, Williams SG, Sweeney CJ; ICECaP Working Group. Xie W, et al. Among authors: fizazi k. J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub 2017 Aug 10. J Clin Oncol. 2017. PMID: 28796587 Free PMC article.
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis.
Turco F, Gillessen S, Treglia G, Fizazi K, Smith MR, Tombal B, Cathomas R, Buttigliero C, Di Maio M, Tucci M, Vogl UM. Turco F, et al. Among authors: fizazi k. Prostate Cancer Prostatic Dis. 2024 Sep;27(3):385-392. doi: 10.1038/s41391-023-00775-y. Epub 2023 Dec 14. Prostate Cancer Prostatic Dis. 2024. PMID: 38097723 Review.
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K; PEACE-1 investigators. Bossi A, et al. Among authors: fizazi k. Lancet. 2024 Nov 23;404(10467):2065-2076. doi: 10.1016/S0140-6736(24)01865-8. Lancet. 2024. PMID: 39580202 Clinical Trial.
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.
Uemura M, Kikukawa H, Hashimoto Y, Uemura H, Mizokami A, Kato M, Matsushima H, Kosaka T, Nakamura M, Fukasawa S, Smith MR, Tombal B, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kakiuchi H, Akiyama M, Li R, Kuss I, Joensuu H, Suzuki H. Uemura M, et al. Among authors: fizazi k. Cancer Med. 2024 Nov;13(21):e70029. doi: 10.1002/cam4.70029. Cancer Med. 2024. PMID: 39527466 Free PMC article. Clinical Trial.
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Azad AA, et al. Among authors: fizazi k. Eur J Cancer. 2024 Dec;213:115078. doi: 10.1016/j.ejca.2024.115078. Epub 2024 Oct 20. Eur J Cancer. 2024. PMID: 39486165 Free article. Clinical Trial.
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo PV, Zarif TE, McClure H, Davidsohn M, Eid M, Spinelli GP, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre RP, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E; SPARTACUSS Group. Patrikidou A, et al. Among authors: fizazi k. Clin Genitourin Cancer. 2024 Dec;22(6):102230. doi: 10.1016/j.clgc.2024.102230. Epub 2024 Oct 5. Clin Genitourin Cancer. 2024. PMID: 39461026 Free article.
541 results